Gateway Wealth Partners LLC Sells 15,431 Shares of Abbott Laboratories $ABT

Key Points

• Gateway Wealth Partners cut its Abbott Laboratories stake by 64.3% in the second quarter, selling 15,431 shares and retaining 8,564 shares valued at approximately $777,000. Institutional investors collectively own 75.18% of ABT.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $118.67. Recent upgrades include Wolfe Research’s move to “outperform” and BTIG’s $134 target.
• Abbott reported quarterly EPS and revenue above expectations, with revenue rising 13% year over year, and pays a $0.63 quarterly dividend. Growth opportunities include diabetes devices, although weaker respiratory-testing demand is tempering diagnostics momentum.

Gateway Wealth Partners LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 64.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,564 shares of the healthcare product maker's stock after selling 15,431 shares during the quarter. Gateway Wealth Partners LLC's holdings in Abbott Laboratories were worth $777,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Symphony Financial Ltd. Co. raised its position in shares of Abbott Laboratories by 2.3% in the 2nd quarter. Symphony Financial Ltd. Co. now owns 15,901 shares of the healthcare product maker's stock worth $1,473,000 after acquiring an additional 363 shares in the last quarter. St. Johns Investment Management Company LLC boosted its position in Abbott Laboratories by 1.0% during the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker's stock valued at $895,000 after purchasing an additional 101 shares in the last quarter. Eagle Bay Advisors LLC grew its stake in Abbott Laboratories by 3.4% in the second quarter. Eagle Bay Advisors LLC now owns 8,346 shares of the healthcare product maker's stock valued at $757,000 after purchasing an additional 274 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in Abbott Laboratories in the second quarter worth about $108,000. Finally, Ascent Group LLC raised its holdings in Abbott Laboratories by 11.5% in the second quarter. Ascent Group LLC now owns 32,662 shares of the healthcare product maker's stock worth $2,964,000 after purchasing an additional 3,365 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on ABT. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target on the stock in a report on Thursday, August 13th. Weiss Ratings upgraded Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. BTIG Research raised their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Finally, Citigroup increased their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.67.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New diabetes-device opportunity: Medtronic has begun shipping its MiniMed Flex insulin pump, which uses an Abbott-made glucose sensor. The launch and accompanying marketing campaign could expand Abbott’s sensor presence in the growing diabetes-care market. MiniMed starts shipping new insulin pump with Abbott-made sensor
• Positive Sentiment: Underlying business remains diversified: Analyst commentary highlights Abbott’s established diagnostics, medical-device and nutrition franchises, along with long-term growth opportunities. Its latest reported quarter also exceeded consensus earnings and revenue estimates, with revenue up 13% year over year. Ken Griffin Just Loaded Up on AbbVie and Abbott
• Neutral Sentiment: Formula litigation clarity: Abbott agreed to pay approximately $670 million to resolve the Gill case and about 2,000 additional necrotizing-enterocolitis claims without admitting liability. The settlement is costly, but it removes uncertainty tied to a large jury award and provides greater visibility into remaining litigation exposure. How Investors Are Reacting To Abbott Laboratories US$670 Million NEC Settlement
• Neutral Sentiment: Investor comparisons are favorable but valuation-sensitive: Articles describe Abbott as a potential long-term healthcare and dividend investment, though comparisons with Envista, Intuitive Surgical, Thermo Fisher and Johnson & Johnson emphasize differing growth, recovery and valuation profiles. NVST or ABT: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Diagnostics growth is uneven: Weaker respiratory-testing demand is offsetting healthy routine testing and approximately 13% growth in cancer diagnostics. This mix could moderate near-term Diagnostics momentum despite strength in higher-growth categories. Here’s What Is Shaping Abbott’s Diagnostics Growth

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $116.70 on Tuesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company's 50 day moving average is $100.64 and its 200 day moving average is $100.03. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $201.94 billion, a PE ratio of 37.77, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source